U.S. Markets closed

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
50.18-0.57 (-1.12%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close50.75
Open50.98
Bid45.00 x 1100
Ask55.00 x 1200
Day's Range49.36 - 50.98
52 Week Range13.04 - 54.85
Volume328,344
Avg. Volume577,021
Market Cap2.457B
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-0.44
Earnings DateOct 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.33
  • CareDx (CDNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
    Zacks

    CareDx (CDNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

    CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Tenet Healthcare's (THC) Earnings Beat in Q3, Improve Y/Y
    Zacks

    Tenet Healthcare's (THC) Earnings Beat in Q3, Improve Y/Y

    Tenet Healthcare's (THC) third-quarter earnings gain from the Ambulatory segment and lower expenses.

  • CareDx Showcases Leading Transplant Data at ASN 2020
    GlobeNewswire

    CareDx Showcases Leading Transplant Data at ASN 2020

    General nephrologists show a growing interest in AlloSure with 11 abstracts and educational symposiums at the largest nephrology meetingSOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a leading presence with AlloSure education at the American Society of Nephrology (ASN) annual conference from October 22 – 25, 2020. The ASN annual conference, otherwise known as Kidney Week, will be run virtually this year. Eleven clinical abstracts on AlloSure have been selected for presentation during the poster and publication sessions of the conference, indicating that general nephrologists have a growing interest in surveillance tools for transplant patient management. CareDx also provided a grant for the educational symposium Diagnostic Controversies in Transplantation: Of Biomarkers and Biopsies.CareDx will host an Exhibitor Spotlight titled AlloSure as a Tool for Surveillance of Renal Transplant Patients: Real-World Evidence and Clinical Utility. During the spotlight session, five nephrologists will discuss their experiences with AlloSure and how it has benefitted their practice and their patients. The speakers and topics will be: * Dr. Vasil Peev, Rush University: Clinical Utility of Kidney Transplant Surveillance with AlloSure * Dr. Sanjiv Anand, Intermountain Medical Center: Baseline Characteristics and Relative Change Value of AlloSure * Dr. Tarek Alhamad, Barnes-Jewish Hospital: AlloSure as a Predictor of Clinical Outcomes * Dr. Nicole Ali, NYU Langone Health: COVID-19 and Renal Transplantation: The NYU Experience * Dr. Adit Mahale, Metrolina Nephrology Associates: AlloSure Experience in the Community “I am looking forward to presenting real-world AlloSure surveillance data across 1000 patients from multiple centers. It is really positive to see confirmation of the validation data in a cohort of real-world transplant patients, as well as the associations with meaningful clinical outcomes,” said Dr. Tarek Alhamad, Associate Professor and Medical Director of Transplant Nephrology at Washington University School of Medicine.“ASN is a tremendous opportunity for the nephrology community to share their experiences and to talk about best practices in kidney care for patients. This conference allows us to update the general nephrologists on the work that CareDx is doing to further clinical practice in transplant patient management,” said Peter Maag, CEO of CareDx.About CareDx CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.CONTACTS:CareDx, Inc. Sasha King Chief Marketing Officer 415-287-2393 sking@caredx.comInvestor Relations Greg Chodaczek 347-620-7010 investor@caredx.com